PMID- 30031495
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1557-8240 (Electronic)
IS  - 0031-3955 (Linking)
VI  - 65
IP  - 4
DP  - 2018 Aug
TI  - Systemic Lupus Erythematosus, Sjogren Syndrome, and Mixed Connective Tissue 
      Disease in Children and Adolescents.
PG  - 711-737
LID - S0031-3955(18)30040-3 [pii]
LID - 10.1016/j.pcl.2018.04.001 [doi]
AB  - Juvenile systemic lupus erythematosus (jSLE), mixed connective tissue disease 
      (jMCTD), and Sjogren syndrome (jSS) are systemic autoimmune and inflammatory 
      disorders with distinct patterns of organ involvement. All are characterized by 
      autoantibody formation, with antinuclear (ANA) and anti-double-stranded DNA 
      common in jSLE, ANA with high-titer ribonucleoprotein antibody in jMCTD, and 
      Sjogren syndrome A and Sjogren syndrome B antibodies + ANA in jSS. Recognition, 
      monitoring, and management for primary care providers are discussed, focusing on 
      the role of primary physicians in recognizing and helping maintain optimal health 
      in children with these potentially life-threatening diseases.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Tarvin, Stacey E
AU  - Tarvin SE
AD  - Division of Rheumatology, Department of Pediatrics, University of Indiana School 
      of Medicine, Riley Hospital for Children at Indiana University Health, 699 Riley 
      Hospital Drive, Riley Research 307, Indianapolis, IN 46202, USA.
FAU - O'Neil, Kathleen M
AU  - O'Neil KM
AD  - Division of Rheumatology, Department of Pediatrics, University of Indiana School 
      of Medicine, Riley Hospital for Children at Indiana University Health, 699 Riley 
      Hospital Drive, Riley Research 307, Indianapolis, IN 46202, USA. Electronic 
      address: kmoneil@iu.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pediatr Clin North Am
JT  - Pediatric clinics of North America
JID - 0401126
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adolescent
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Child
MH  - Diagnosis, Differential
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - *Lupus Erythematosus, Systemic/complications/diagnosis/therapy
MH  - *Mixed Connective Tissue Disease/diagnosis/therapy
MH  - Pediatricians
MH  - Prognosis
MH  - *Sjogren's Syndrome/diagnosis/therapy
OTO - NOTNLM
OT  - Antinuclear antibodies
OT  - Autoantibodies
OT  - Juvenile Sjogren syndrome
OT  - Juvenile mixed connective tissue disease
OT  - Juvenile systemic lupus erythematosus
OT  - Lupus nephritis
EDAT- 2018/07/23 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/07/23 06:00
PHST- 2018/07/23 06:00 [entrez]
PHST- 2018/07/23 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
AID - S0031-3955(18)30040-3 [pii]
AID - 10.1016/j.pcl.2018.04.001 [doi]
PST - ppublish
SO  - Pediatr Clin North Am. 2018 Aug;65(4):711-737. doi: 10.1016/j.pcl.2018.04.001.